Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
复制标题
DOI：
10.1182/blood-2012-05-378943
复制
发表时间：
2012-08-09
期刊：
影响因子：
20.3
通讯作者：
Relling, Mary V.
中科院分区：
文献类型：
--
作者：
Pui, Ching-Hon;Mullighan, Charles G.;Relling, Mary V.
改进的支持性治疗、更精确的风险分层和基于白血病细胞和宿主特征的个性化化疗（例如药代动力学和药物遗传学）已将儿童急性淋巴细胞白血病的治愈率推高至近90%。通过发现更多复发性分子病变，再加上通过高通量基因组学和创新药物筛选系统开发新的靶向治疗，可以预期治愈率的进一步提高。我们讨论了一些特定的研究领域，这些领域有望进一步完善目前的治疗方法，提高患者的治愈率和生活质量。（血。2012;120（6）：1165-1174）
Improved supportive care, more precise risk stratification, and personalized chemotherapy based on the characteristics of leukemic cells and hosts (eg, pharmacokinetics and pharmacogenetics) have pushed the cure rate of childhood acute lymphoblastic leukemia to near 90%. Further increase in cure rate can be expected from the discovery of additional recurrent molecular lesions, coupled with the development of novel targeted treatment through high-throughput genomics and innovative drug-screening systems. We discuss specific areas of research that promise to further refine current treatment and to improve the cure rate and quality of life of the patients. (Blood. 2012;120(6):1165-1174)